for HD Chorea in Adults

Go about
your day
with reduced
uncontrollable movements1

People taking AUSTEDO saw

With AUSTEDO XR there was more than twice the reduction in Huntington’s Disease vs placebo in 12 weeks compared to placebo

in Huntington’s disease (HD) chorea
vs placebo in a 12-week study1,*

*4.4-point improvement in people taking AUSTEDO vs 1.9 in people taking placebo based on Total Maximal Chorea (TMC) score. The TMC score is used to measure HD chorea movements in the face, mouth, trunk, both arms, and both legs.1,2

9 out of 10 people on AUSTEDO XR said their movement control had improved since starting treatment

said their movement control had improved since starting treatment2, †

Results from a real-world survey including 31 patients with HD chorea taking AUSTEDO XR.

Established safety results for

ESTABLISHED SAFETY RESULTS FOR ABOUT 3 YEARS

This was an open-label study, which is a drug trial in which all participants are aware of the drug being tested.

In clinical trials

93% of adults continued taking AUSTEDO XR without needing to reduce their dose due to side effects

continued taking AUSTEDO XR without
needing to reduce their dose due to side effects1

Once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets contain the same active ingredient as twice-daily AUSTEDO (deutetrabenazine) tablets.
Data on this page is based on twice-daily dosing.1

51 percent of HD patients on Austedo saw treatment success. 42 percent of doctors saw treatment success.

People reported improvement in HD chorea symptoms1,2

People with HD chorea on AUSTEDO rated symptoms as “very much improved” or “much improved” at 12 weeks with AUSTEDO.

§Treatment success is measured by perceived improvement in TMC score.

51 percent of Huntington’s Disease patients on Austedo saw treatment success

People taking AUSTEDO XR reported being more physically capable of performing everyday tasks.2,4

  • Climbing stairs
  • Bending, kneeling, or stooping
  • Lifting/carrying groceries
  • Walking
  • Dressing
  • Bathing
  • Moderate to vigorous activities
People taking AUSTEDO XR were more physically capable of performing everyday tasks

People taking AUSTEDO achieved greater improvement in the SF-36 Physical Functioning Score at 12 weeks vs placebo.

See study details

SF-36=36-Item Short Form Health Survey assessing health-related quality of life.

AUSTEDO XR/AUSTEDO does not cure the cause of the involuntary movements and it does not
treat the other symptoms of HD, such as problems with thinking or emotions.1

See why Ray and Rhonda made the decision to treat HD chorea.

See why Ray and Rhonda made the decision to treat HD chorea

When HD chorea threatened to disrupt Ray and Rhonda's retirement plans, they knew it was time to ask Ray's doctor about treatment options.

Track your progress

Download the HD Chorea Treatment Tracking Guide to record when
AUSTEDO XR is taken and note any questions for your healthcare provider.

Treatment Tracking Guide

Start the conversation now

Whether you're ready to start medication or planning
ahead, talking to a healthcare provider (for example, your doctor or nurse practitioner) is an important step.

Check out the guide

References:

1. AUSTEDO XR® (deutetrabenazine) extended-release tablets/AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

3. Frank S, Testa CM, Stamler D, et al; Huntington Study Group ARC-HD Investigators. Long-term efficacy and safety of deutetrabenazine for chorea in Huntington's disease: results from the ARC-HD open-label study. Poster presented at: 27th Annual Meeting of the Huntington Study Group (HSG); October 29-31, 2020.

4. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington's Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington's Disease Society of America; 2014. Accessed January 24, 2024. http://hdsa.org/wp-content/uploads/2015/04/CaregiverGuide_Mid_Late_StageHD.pdf